Molecular Biology Reports

, Volume 39, Issue 10, pp 9661–9668 | Cite as

Polymorphisms in TP53 and MDM2 contribute to higher risk of colorectal cancer in Chinese population: a hospital-based, case–control study

  • Yuxing Zhang
  • Li Liu
  • Yingchun Tang
  • Chao Chen
  • Qian Wang
  • Jun Xu
  • Chao Yang
  • Xiaoping Miao
  • Sheng Wei
  • Jigui Chen
  • Shaofa Nie


The murine double minute 2 protein (MDM2) and TP53 interact in regulating cell cycle, DNA repair and apoptosis process, which is crucial in carcinogenesis. Since functional variations in these two genes were shown to change gene expression and function, we hypothesized that potentially functional polymorphisms in these genes may contribute to colorectal cancer (CRC) susceptibility. A hospital-based case–control study consisting of 444 patients and 569 controls was conducted to explore the associations between TP53 Arg72Pro and MDM2 T309G and CRC risk in Chinese. The combined effect of TP53 Arg72Pro and MDM2 T309G was significant in a gene dose–response increasing CRC risk (trend test: P = 0.02). Individuals carrying 3 or more potential risk alleles had 1.78 times risk (95 % CI: 1.13–2.80) to develop CRC compared with individuals without potential risk allele. This increased cancer risk was more pronounced in smokers who carried 3–4 potential risk alleles (OR = 2.75, 95 % CI: 1.14–6.60) and in young subjects (OR = 2.05, 95 % CI: 1.08–3.88). The gene–gene interaction between TP53 Arg72Pro and MDM2 T309G may interact in carcinogenesis of CRC in Chinese, especially in smokers, and this kind of interaction is associated with onset age of CRC.


TP53 MDM2 Polymorphism Colorectal cancer 



This work was supported by the project of the Ministry of Finance and Health of China (2009–193, Jigui Chen, principal investigator), the National Natural Science Foundation of China (NSFC-30972534 and NSFC-81172752, Shaofa Nie, principal investigator). We thank all the patients and controls participated in this study for their cooperation and Chang Liu (Department of Surgery, The Eighth Hospital of Wuhan City) for her effort in collection of clinical samples and epidemiological data.

Conflict of interests

There is no conflict of interests.


  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917PubMedCrossRefGoogle Scholar
  2. 2.
    de la Chapelle A (2004) Genetic predisposition to colorectal cancer. Nat Rev Cancer 4:769–780PubMedCrossRefGoogle Scholar
  3. 3.
    Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300PubMedCrossRefGoogle Scholar
  4. 4.
    Wan DS (2009) Epidemiologic trend of and strategies for colorectal cancer. Ai Zheng 28:897–902PubMedGoogle Scholar
  5. 5.
    Marte B (2002) Cancer: super p53. Nature 420:279PubMedCrossRefGoogle Scholar
  6. 6.
    Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445:661–665PubMedCrossRefGoogle Scholar
  7. 7.
    Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S (2009) Suppression of induced pluripotent stem cell generation by the p53–p21 pathway. Nature 460:1132–1135PubMedCrossRefGoogle Scholar
  8. 8.
    Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365PubMedCrossRefGoogle Scholar
  9. 9.
    Hamajima N, Matsuo K, Suzuki T, Nakamura T, Matsuura A, Hatooka S, Shinoda M, Kodera Y, Yamamura Y, Hirai T, Kato T, Tajima K (2002) No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett 181:81–85PubMedCrossRefGoogle Scholar
  10. 10.
    Zhu ZZ, Wang AZ, Jia HR, Jin XX, He XL, Hou LF, Zhu G (2007) Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol 37:385–390PubMedCrossRefGoogle Scholar
  11. 11.
    Misra C, Majumder M, Bajaj S, Ghosh S, Roy B, Roychoudhury S (2009) Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer. Mol Carcinog 48:790–800PubMedCrossRefGoogle Scholar
  12. 12.
    Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, Bono P, Arola J, Jarvinen HJ, Mecklin JP, Atula T, Kontio R, Makitie AA, Suominen S, Leivo I, Vahteristo P, Aaltonen LM, Aaltonen LA (2005) The MDM2 promoter polymorphism SNP309T–>G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 42:694–698PubMedCrossRefGoogle Scholar
  13. 13.
    Levav-Cohen Y, Haupt S, Haupt Y (2005) MDM2 in growth signaling and cancer. Growth Factors 23:183–192PubMedCrossRefGoogle Scholar
  14. 14.
    Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591–602PubMedCrossRefGoogle Scholar
  15. 15.
    Xu B, Xu Z, Cheng G, Min ZC, Mi Y, Zhang ZZ, Tao J, Li PC, Wang ML, Tang JL, Zhang ZD, Zhang W, Wu HF, Feng NH, Hua LX (2010) Association between polymorphisms of TP53 and MDM2 and prostate cancer risk in southern Chinese. Cancer Genet Cytogenet 202:76–81PubMedCrossRefGoogle Scholar
  16. 16.
    Buetow KH, Edmonson M, MacDonald R, Clifford R, Yip P, Kelley J, Little DP, Strausberg R, Koester H, Cantor CR, Braun A (2001) High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci USA 98:581–584PubMedCrossRefGoogle Scholar
  17. 17.
    Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307–310PubMedCrossRefGoogle Scholar
  18. 18.
    Vousden KH, Lu X (2002) Live or let die: the cell’s response to p53. Nat Rev Cancer 2:594–604PubMedCrossRefGoogle Scholar
  19. 19.
    Yap DB, Hsieh JK, Chan FS, Lu X (1999) MDM2: a bridge over the two tumour suppressors, p53 and Rb. Oncogene 18:7681–7689PubMedCrossRefGoogle Scholar
  20. 20.
    Moll UM, Petrenko O (2003) The MDM2-p53 interaction. Mol Cancer Res 1:1001–1008PubMedGoogle Scholar
  21. 21.
    Mo P, Wang H, Lu H, Boyd DD, Yan C (2010) MDM2 mediates ubiquitination and degradation of activating transcription factor 3. J Biol Chem 285:26908–26915PubMedCrossRefGoogle Scholar
  22. 22.
    Chen L, Li Z, Zwolinska AK, Smith MA, Cross B, Koomen J, Yuan ZM, Jenuwein T, Marine JC, Wright KL, Chen J (2010) MDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output. EMBO J 29:2538–2552PubMedCrossRefGoogle Scholar
  23. 23.
    Barak Y, Juven T, Haffner R, Oren M (1993) MDM2 expression is induced by wild type p53 activity. EMBO J 12:461–468PubMedGoogle Scholar
  24. 24.
    Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80–83PubMedCrossRefGoogle Scholar
  25. 25.
    Ouban A, Dellis J, Salup R, Morgan M (2003) Immunohistochemical expression of MDM2 and p53 in penile verrucous carcinoma. Ann Clin Lab Sci 33:101–106PubMedGoogle Scholar
  26. 26.
    Shiina H, Igawa M, Shigeno K, Yamasaki Y, Urakami S, Yoneda T, Wada Y, Honda S, Nagasaki M (1999) Clinical significance of MDM2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis. Oncology 56:239–247PubMedCrossRefGoogle Scholar
  27. 27.
    Shwe M, Chiguchi G, Yamada S, Nakajima T, Maung KK, Takagi M, Amagasa T, Tsuchida N (2001) P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas. J Med Dent Sci 48:113–119PubMedGoogle Scholar
  28. 28.
    Vazquez A, Bond EE, Levine AJ, Bond GL (2008) The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 7:979–987PubMedCrossRefGoogle Scholar
  29. 29.
    Venot C, Maratrat M, Dureuil C, Conseiller E, Bracco L, Debussche L (1998) The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J 17:4668–4679PubMedCrossRefGoogle Scholar
  30. 30.
    Pim D, Banks L (2004) p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108:196–199PubMedCrossRefGoogle Scholar
  31. 31.
    Fang S, Krahe R, Lozano G, Han Y, Chen W, Post SM, Zhang B, Wilson CD, Bachinski LL, Strong LC, Amos CI (2010) Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One 5:e10813PubMedCrossRefGoogle Scholar
  32. 32.
    Wang JJ, Zheng Y, Sun L, Wang L, Yu PB, Dong JH, Zhang L, Xu J, Shi W, Ren YC (2011) TP53 codon 72 polymorphism and colorectal cancer susceptibility: a meta-analysis. Mol Biol Rep 38:4847–4853PubMedCrossRefGoogle Scholar
  33. 33.
    Dahabreh IJ, Linardou H, Bouzika P, Varvarigou V, Murray S (2010) TP53 Arg72Pro polymorphism and colorectal cancer risk: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 19:1840–1847PubMedCrossRefGoogle Scholar
  34. 34.
    Cao X, Zhang T, Zhao Z, Zhao T (2012) MDM2 SNP309 polymorphism and colorectal cancer risk: a meta-analysis. DNA Cell Biol 31:354–358CrossRefGoogle Scholar
  35. 35.
    Yang M, Guo Y, Zhang X, Miao X, Tan W, Sun T, Zhao D, Yu D, Liu J, Lin D (2007) Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 28:1996–2001PubMedCrossRefGoogle Scholar
  36. 36.
    Joshi AM, Budhathoki S, Ohnaka K, Mibu R, Tanaka M, Kakeji Y, Maehara Y, Okamura T, Ikejiri K, Futami K, Maekawa T, Yasunami Y (2011) TP53 R72P and MDM2 SNP309 polymorphisms and colorectal cancer risk: the Fukuoka colorectal cancer study. Jpn J Clin Oncol 41:232–238PubMedCrossRefGoogle Scholar
  37. 37.
    Chua HW, Ng D, Choo S, Lum SS, Li H, Soh LY, Sabapathy K, Seow A (2010) Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore. BMC Cancer 10:88PubMedCrossRefGoogle Scholar
  38. 38.
    Ihsan R, Devi TR, Yadav DS, Mishra AK, Sharma J, Zomawia E, Verma Y, Phukan R, Mahanta J, Kataki AC, Kapur S, Saxena S (2010) Investigation on the role of p53 codon 72 polymorphism and interactions with tobacco, betel quid, and alcohol in susceptibility to cancers in a high-risk population from North East India. DNA Cell Biol 30:163–171PubMedCrossRefGoogle Scholar
  39. 39.
    Caceres DD, Quinones LA, Schroeder JC, Gil LD, Irarrazabal CE (2009) Association between p53 codon 72 genetic polymorphism and tobacco use and lung cancer risk. Lung 187:110–115PubMedCrossRefGoogle Scholar
  40. 40.
    Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, Wang Y, Lin D (2006) Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 27:110–117PubMedCrossRefGoogle Scholar
  41. 41.
    Bond GL, Menin C, Bertorelle R, Alhopuro P, Aaltonen LA, Levine AJ (2006) MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet 43:950–952PubMedCrossRefGoogle Scholar
  42. 42.
    Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, Belluco C, Montagna M, Agata S, D’Andrea E, Nitti D, Amadori A, Bertorelle R (2006) Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 98:285–288PubMedCrossRefGoogle Scholar
  43. 43.
    Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, Chompret A, Bressac-de Paillerets B, Stoppa-Lyonnet D, Bonaiti-Pellie C, Frebourg T (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43:531–533PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Yuxing Zhang
    • 1
  • Li Liu
    • 2
  • Yingchun Tang
    • 1
  • Chao Chen
    • 1
  • Qian Wang
    • 1
  • Jun Xu
    • 1
  • Chao Yang
    • 1
  • Xiaoping Miao
    • 2
  • Sheng Wei
    • 2
  • Jigui Chen
    • 1
  • Shaofa Nie
    • 2
  1. 1.Department of SurgeryThe Eighth Hospital of Wuhan CityWuhanChina
  2. 2.Department of Epidemiology and BiostatisticsSchool of Public Health, Tongji Medical College, Huazhong University of Science and TechnologyWuhanChina

Personalised recommendations